AUTHOR=Kiss Zoltán , Bogos Krisztina , Tamási Lilla , Ostoros Gyula , Müller Veronika , Urbán László , Bittner Nora , Sárosi Veronika , Vastag Aladár , Polányi Zoltán , Nagy-Erdei Zsófia , Daniel Andrea , Vokó Zoltán , Nagy Balázs , Horvath Krisztian , Rokszin MD György , Abonyi-Tóth Zsolt , Barcza Zsófia , Gálffy Gabriella , Moldvay Judit 

TITLE=Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 27 - 2021

YEAR=2021

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2021.603937

DOI=10.3389/pore.2021.603937

ISSN=1532-2807

ABSTRACT=Objective: Lung cancer is one of the most common cancers worldwide and its survival is still poor. The objective of our study was to estimate long-term survival of Hungarian lung cancer patients at first time based on a nationwide review of the National Health Insurance Fund (NHIF) database.
Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between 1 January 2011 and 31 December 2016. Survival rates were evaluated by year of diagnosis, patient gender and age, and morphology of lung cancer. 
Results: 41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and 65.9 years during study period. One- and 5-year overall survival rates for the total population were 42.2% and 17.9%, respectively. Survival was statistically associated with gender, age and type of lung cancer. Female patients (n=16,362) had 23% better survival (HR: 0.77, 95% confidence interval(CI): 0.75-0.79; p<0.001) than males (n=25,492). The highest survival rates were found in the 20–49 age cohort (5Y=31.3%) and if the cancer type was adenocarcinoma (5Y=20.5%). We measured 5.3 % improvement (9,2% adjusted) in lung cancer survival comparing the period 2015-2016 to. 2011-2012 (HR: 0.95 95% CI: 0.92-0.97; p=0.003), the highest at females <60 year (0.86 	 (adjusted HR was 0.79), interaction analysis was significant for age and histology types.
Conclusion: Our study provided long-term LC survival data in Hungary for the first time. We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients had better survival. Survival rates were comparable to – and at the higher end of – rates registered in other East-Central European countries (7.7%-15.7%).